Synlogic

Synthetically engineered, therapeutic microbes

SYNB1353 Clin1 homocystinuria; SYNB8802 Clin1 enteric hyperoxaluria; SYNB2081 Clin0 gout; 2 undisclosed programs Clin0 IBD

Synlogic is focused on developing innovative synthetic biotic medicines for a range of diseases. Their unique approach involves using their Synthetic Biotic platform to engineer commensal bacteria to produce therapeutic molecules within the body. With this process, they can create GI-restricted, oral medicines designed to consume or modify disease-specific metabolites. Synlogic is developing treatments for inborn errors of metabolism, such as phenylketonuria (PKU) and urea cycle disorders. They are also exploring the potential of synthetic biotics for treating inflammatory diseases, to target cancer cells, and modulate the immune system. Their lead candidate is SYNB1353, a novel, non-systemically absorbed drug designed to lower homocysteine levels in patients with the rare metabolic disease classical homocystinuria (HCU).